TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10708814

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg naloxone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study: 9010612

Group type: EXPERIMENTAL
Intervention: RW94
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1894523

Group type: EXPERIMENTAL
Intervention: Lung hyperinflation and suctioning (three lung hyperinflation breaths at volumes of 12 cc/kg, 14 cc/kg, 16 cc/kg, or 18 cc/kg of lean body weight, followed by 10 seconds of continuous suction)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lung hyperinflation and suctioning
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Suctioning
Number of subjects: 26
Study: 6873137

Group type: EXPERIMENTAL
Intervention: Scopolamine 6 micrograms/kg (intravenous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.3 mg and 0.9 mg (oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.9 mg b.d. for 3 days (oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ephedrine (alone and in combination with scopolamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.9 mg (oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine (various doses)
Number of subjects: 0
Study: 31797791

Group type: EXPERIMENTAL
Intervention: Pegilodecakin combined with pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegilodecakin combined with nivolumab
Number of subjects: 0
Study: 27935259

Group type: EXPERIMENTAL
Intervention: Manuka honey (MH) sinus irrigation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (SAL) sinus irrigation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Manuka honey (MH) sinus irrigation (in subset not receiving oral antibiotics/steroids)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (SAL) sinus irrigation (in subset not receiving oral antibiotics/steroids)
Number of subjects: 42
Study: 26993345

Group type: EXPERIMENTAL
Intervention: Liposomal methylene blue (LMB) + Intense Pulsed Light (IPL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intense Pulsed Light (IPL) alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: LMB + IPL
Number of subjects: 35

Group type: COMPARATOR
Intervention: IPL alone
Number of subjects: 35
Study: 25128002

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 500

Group type: COMPARATOR
Intervention: Pelvic floor muscle training plus solifenacin (5 mg once daily)
Number of subjects: 500
Study: 22899693

Group type: EXPERIMENTAL
Intervention: xylitol‐wipe
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo‐wipe
Number of subjects: 44
Study: 19640952

Group type: EXPERIMENTAL
Intervention: High-protein, carbohydrate-free diet (H diet; 30% protein, 0% carbohydrate, 70% fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal-protein diet (N condition; 12% protein, 55% carbohydrate, 33% fat)
Number of subjects: 10
Study: 17210771

Group type: EXPERIMENTAL
Intervention: Posaconazole at 800 mg/day as an oral suspension in divided doses
Number of subjects: 12
Study: 10863225

Group type: EXPERIMENTAL
Intervention: Augmented betamethasone dipropionate 0.05% cream once daily in the first and third weeks and calcipotriene 0.005% ointment twice daily in the second and fourth weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Daily augmented betamethasone dipropionate 0.05% cream for 4 weeks
Number of subjects: 52
Study: 9176849

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 31
Study: 1356176

Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg every 12 h via nasogastric tube until 24 h after extubation (n = 38)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo every 12 h via nasogastric tube until 24 h after extubation (n = 32)
Number of subjects: 70
Study: 4047067

Group type: EXPERIMENTAL
Intervention: Proxyphylline (oral treatment)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proxyphylline (after exercise-induced asthma)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proxyphylline (pharmacokinetics)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proxyphylline (overall efficacy)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proxyphylline (safety)
Number of subjects: 15
Study: 30446432

Group type: EXPERIMENTAL
Intervention: Serum from incident-T2DM patients
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Fasting and 4 h-postprandial PBMCs from incident-T2DM patients
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Fasting/postprandial levels of splicing machinery components in PBMCs
Number of subjects: 215
Study: 26993881

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg/3 mL intramuscular)
Number of subjects: 1644

Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g/100 mL intravenous)
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg intravenous)
Number of subjects: 1644

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 1644

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 1644
Study: 24079852

Group type: EXPERIMENTAL
Intervention: Brodalumab 70 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 22313885

Group type: EXPERIMENTAL
Intervention: Qingre Huayu herbs plus classic Western medical treatment (treatment group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Classic Western medical treatment (control group)
Number of subjects: 98
Study: 20040164

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18404579

Group type: EXPERIMENTAL
Intervention: 5-finger method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual memorization method
Number of subjects: 50
Study: 15844715

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No-fiber polymeric diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diet (control group)
Number of subjects: 0
Study: 12431146

Group type: EXPERIMENTAL
Intervention: Ambulation 3 hours after catheter or sheath removal
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ambulation 6 hours after catheter or sheath removal
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups (3-H and 6-H)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ambulation 3 hours after diagnostic angiography
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ambulation 6 hours after diagnostic angiography
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Early ambulation after angiography
Number of subjects: 110
Study: 10488294

Group type: EXPERIMENTAL
Intervention: Flumazenil administered at the conclusion of the surgical procedure
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo administered at the conclusion of the surgical procedure
Number of subjects: 110
Study: 8814687

Group type: EXPERIMENTAL
Intervention: Resection-line involvement
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: T3 and T4 stage
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: N(+) stage
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Tumour differentiation
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Presence of resection-line involvement
Number of subjects: 699
Study: 1755934

Group type: EXPERIMENTAL
Intervention: Auditory stimulation with placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Biperiden (4 mg)
Number of subjects: 12
Study: 31860537

Group type: EXPERIMENTAL
Intervention: 300,000 IU of vitamin D3 once (stoss group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 50,000 IU of vitamin D3 once weekly for 6 weeks (standard of care, SOC group)
Number of subjects: 44
Study: 30809995

Group type: EXPERIMENTAL
Intervention: Core stability training (CST) on an unstable support surface (USS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Core stability training (CST) on a stable support surface (SSS)
Number of subjects: 29
Study: 28155018

Group type: EXPERIMENTAL
Intervention: Finding My Way online intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: Information-only online control
Number of subjects: 191
Study: 25909236

Group type: EXPERIMENTAL
Intervention: Oral supplementation with 1.2 g ω‐3 fatty acids per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups received warm compresses, lid massage, and artificial tear substitutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 23506367

Group type: EXPERIMENTAL
Intervention: Tobacco deprived condition (n = 51)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nondeprived condition (n = 69)
Number of subjects: 120
Study: 21564406

Group type: EXPERIMENTAL
Intervention: 17α-hydroxyprogesterone caproate 250 mg intramuscularly weekly from 16 weeks' gestation to 37 weeks' gestation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine perinatal care
Number of subjects: 100
Study: 19241234

Group type: EXPERIMENTAL
Intervention: Pushrim-activated, power-assisted wheelchair (PPW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Power wheelchair
Number of subjects: 0
Study: 17267789

Group type: EXPERIMENTAL
Intervention: Panic-focused psychodynamic psychotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Applied relaxation training
Number of subjects: 49
Study: 16105869

Group type: EXPERIMENTAL
Intervention: PI-based HAART (n = 32)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-PI-based HAART (n = 36)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HAART (general)
Number of subjects: 68
Study: 12379156

Group type: EXPERIMENTAL
Intervention: Frisolac Allergycare (FAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nutramigen (NUT)
Number of subjects: 30
Study: 10206131

Group type: EXPERIMENTAL
Intervention: Elective gastric lavage before the first feed (227 neonates)
Number of subjects: 502

Group type: COMPARATOR
Intervention: No gastric lavage prior to feeds (275 neonates)
Number of subjects: 502
Study: 7762843

Group type: EXPERIMENTAL
Intervention: Morphine (up to two IV boluses of 5 mg followed by IV morphine PCA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ketorolac (up to two IV boluses of 30 mg followed by IV ketorolac PCA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Morphine (Group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ketorolac (Group 2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Morphine and Ketorolac (Groups 1 and 2)
Number of subjects: 51
Study: 2308758

Group type: EXPERIMENTAL
Intervention: Self-administration of morphine (PCA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Continuous infusion of morphine
Number of subjects: 58
Study: 6446011

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30740014

Group type: EXPERIMENTAL
Intervention: Valveless Trocar System (VTS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard Trocar
Number of subjects: 200
Study: 27640872

Group type: EXPERIMENTAL
Intervention: Antipsychotic review
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Social interaction intervention
Number of subjects: 187

Group type: COMPARATOR
Intervention: Antipsychotic review and social interaction
Number of subjects: 187
Study: 25520427

Group type: EXPERIMENTAL
Intervention: Antimalarial chemoprevention
Number of subjects: 196

Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Pre-erythrocytic antigens
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Blood-stage antigens
Number of subjects: 196
Study: 24163235

Group type: COMPARATOR
Intervention: Telephone health education (THE)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Telephone counselling (TC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Videophone counselling (VC)
Number of subjects: 52
Study: 21168112

Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Light touch on the SP6 acupoint (Control)
Number of subjects: 30
Study: 19168412

Group type: EXPERIMENTAL
Intervention: Test ciprofloxacin (500 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference ciprofloxacin (500 mg)
Number of subjects: 14
Study: 16737668

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86

Group type: COMPARATOR
Intervention: Acustimulation wristbands
Number of subjects: 86
Study: 15541982

Group type: EXPERIMENTAL
Intervention: Vivostat (autologous fibrin sealant)
Number of subjects: 40
Study: 11378316

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 212

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 212
Study: 9238875

Group type: EXPERIMENTAL
Intervention: PPi/TCS dentifrice (5.0% soluble pyrophosphate/0.145% fluoride as NaF/silica abrasive/0.28% triclosan)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Zn/TCS dentifrice (0.5% zinc citrate trihydrate/0.15% fluoride as sodium monofluorophosphate/silica abrasive/0.20% triclosan)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Gan/TCS dentifrice (2.0% Gantrez acid copolymer/0.145% fluoride as NaF/silica abrasive/0.30% triclosan)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: PPi/TCS dentifrice
Number of subjects: 544

Group type: COMPARATOR
Intervention: Control dentifrice (0.145% fluoride as NaF/silica abrasive)
Number of subjects: 544
Study: 8431747

Group type: EXPERIMENTAL
Intervention: Anaesthetic solution at 42 degrees C
Number of subjects: 136

Group type: COMPARATOR
Intervention: Anaesthetic solution at 10 degrees C
Number of subjects: 136

Group type: COMPARATOR
Intervention: Anaesthetic solution at 18 degrees C
Number of subjects: 136

Group type: COMPARATOR
Intervention: Anaesthetic solution at 37 degrees C
Number of subjects: 136
Study: 3038415

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once-a-day
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 29198543

Group type: EXPERIMENTAL
Intervention: Inhibitors of gastric acidity (H2 blockers or proton pump inhibitors)
Number of subjects: 743
Study: 27654495

Group type: EXPERIMENTAL
Intervention: Free Parking (FP)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 138
Study: 25242051

Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Number of subjects: 32340
Study: 22541755

Group type: EXPERIMENTAL
Intervention: Moprid® (5 mg mosapride citrate tablets)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Gasmotin® (5 mg mosapride citrate tablets)
Number of subjects: 23
Study: 21246849

Group type: EXPERIMENTAL
Intervention: Balance acupuncture on Jiantong point
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture on Shuigou (GV 26), Neiguan (PC 6), Tongli (HT 5), Zusanlti (ST 36), Xuanzhong (GB 39) and others
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Balance acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balance acupuncture vs Conventional acupuncture
Number of subjects: 60
Study: 17589809

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVT) 4 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 16279574

Group type: EXPERIMENTAL
Intervention: Two-stage randomized phase II clinical trial design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive sample size at the second stage
Number of subjects: 0
Study: 12381902

Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 and raltitrexed 2.5 mg/m2 on day 1 and Levofolinic acid 250 mg/m2 and 5‐fluorouracil 900 mg/m2 on day 2 (arm A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cisplatin 65 mg/m2 and methotrexate 500 mg/m2 on day 1 and Levofolinic acid 250 mg/m2 and 5‐fluorouracil 800 mg/m2 on day 2 (arm B)
Number of subjects: 61
Study: 10089866

Group type: EXPERIMENTAL
Intervention: Mode switching algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8524988

Group type: EXPERIMENTAL
Intervention: Mental arithmetic task
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postural change (standing)
Number of subjects: 40
Study: 2177158

Group type: EXPERIMENTAL
Intervention: 1 mg ACTH 4-10
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7410535

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30746674

Group type: EXPERIMENTAL
Intervention: Training by junior teacher
Number of subjects: 66

Group type: COMPARATOR
Intervention: Training by senior teacher
Number of subjects: 66
Study: 27520594

Group type: EXPERIMENTAL
Intervention: Solar-powered odour-baited mosquito trapping systems (SMoTS) installed in 4358 households during the roll-out from June 3, 2013, to May 16, 2015.
Number of subjects: 34041

Group type: COMPARATOR
Intervention: Non-intervened clusters (no SMoTS installed).
Number of subjects: 34041

Group type: EXPERIMENTAL
Intervention: SMoTS clusters (intervened).
Number of subjects: 34041

Group type: COMPARATOR
Intervention: Non-intervened clusters.
Number of subjects: 34041
Study: 24739910

Group type: EXPERIMENTAL
Intervention: 25% water-soluble propolis extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% isotonic saline
Number of subjects: 0
Study: 20922557

Group type: COMPARATOR
Intervention: Doxorubicin plus cyclophosphamide (AC)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus docetaxel
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Docetaxel plus capecitabine
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus gemcitabine
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Taxane-containing regimen
Number of subjects: 338

Group type: COMPARATOR
Intervention: Non-taxane-containing regimen (AC)
Number of subjects: 338
Study: 20516273

Group type: EXPERIMENTAL
Intervention: Meal A (high fat)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Meal B (bulk and low fat)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Meal C (bulk and high fat)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Meal D (high fluid and low fat)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Meal E (200 ml of water)
Number of subjects: 35
Study: 18822919

Group type: EXPERIMENTAL
Intervention: Retention enema with compound glutamine entero‐soluble Capsule (CGC) and oral CGC (0.8 g, thrice a day)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Retention enema with glucocorticoids and metronidazole
Number of subjects: 168
Study: 15907596

Group type: EXPERIMENTAL
Intervention: FURP-lamivudine (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epivir (reference formulation)
Number of subjects: 24
Study: 12870818

Group type: EXPERIMENTAL
Intervention: Aphasic patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (Aphasic and Control)
Number of subjects: 21
Study: 11052308

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 41
Study: 8867907

Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms in 1 ml saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Galanin (10 micrograms/kg in 100 ml saline) infusion for 60 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined administration of galanin (10 micrograms/kg in 100 ml saline) and GHRH (100 micrograms in 1 ml saline)
Number of subjects: 20
Study: 1611439

Group type: EXPERIMENTAL
Intervention: MF 701 (100 mg intramuscularly once a day)
Number of subjects: 324

Group type: COMPARATOR
Intervention: UFH (5000 units subcutaneously three times daily)
Number of subjects: 324
Study: 6608336

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP), 200 mg orally
Number of subjects: 26
Study: 31299912

Group type: EXPERIMENTAL
Intervention: Community-based intervention including an oral 20-25 min presentation in the language of participants about cervical cancer and screening.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-randomized control group (neighboring areas).
Number of subjects: 0
Study: 29862484

Group type: EXPERIMENTAL
Intervention: Food additive exposure (xanthan gum, carrageenan, maltodextrin, soy lecithin)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Total food additive exposure
Number of subjects: 138
Study: 26788923

Group type: EXPERIMENTAL
Intervention: Nuts (+7 kcal/kg bodyweight/day for two months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fruit (+7 kcal/kg bodyweight/day for two months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 25160843

Group type: COMPARATOR
Intervention: Standard Behavioral Weight Loss Program (SBWP)
Number of subjects: 195

Group type: COMPARATOR
Intervention: ADOPT
Number of subjects: 195

Group type: COMPARATOR
Intervention: MAINTAIN
Number of subjects: 195
Study: 22858704

Group type: EXPERIMENTAL
Intervention: Buccal brackets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lingual brackets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-bonded control teeth
Number of subjects: 20
Study: 20359269

Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil (EPO) 3,000 mg per day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Vitamin E 1,200 IU per day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Vitamin E 1,200 IU per day plus EPO 3,000 mg per day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 85
Study: 18786318

Group type: EXPERIMENTAL
Intervention: Heparin 2 mg.kg(‐1).d(‐1) administered continuously via intravenous pump
Number of subjects: 119

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 119